Sift Biosciences
Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases
$3.7MPre-Seed
Role not disclosedSU
SBI US Gateway Fund
Activity from announced rounds
Activity in this selectionPre-seed
SBI US Gateway Fund is the specified investment vehicle named by Sift and Typewriter.
Recorded funding activity
Sift develops peptide immunotherapies using AI and profiling. Typewriter develops RNA-based insertion of therapeutic genes. These financing relationships belong to the named vehicle rather than to every SBI group entity.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.7M 1 disclosed · full round size, not this investor’s share